Analyzers
These analyzers are used for disease testing for heart disease, cancer, diabetes, infectious diseases and hormonal disorders related to lifestyle.
Analyzers
These analyzers are used for disease testing for heart disease, cancer, diabetes, infectious diseases and hormonal disorders related to lifestyle.


AFIAS COVID-19 Ab automated immunoassay in conjunction with AFIAS-1 analyzer
The AFIAS COVID-19 Ab (in conjunction with AFIAS-1 analyzer) is a fluorescence Immunoassay intended for the qualitative detection of IgG/IgM antibodies to SARS-CoV-2 in serum, plasma, venous whole blood or fingerstick capillary whole blood samples from individuals with current or prior COVID-19 infection. The AFIAS COVID-19 Ab is intended for use as an aid in identifying patients with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
AFIAS-1 is an automated immunoassay analyzer that detect or measures the concentration of target analyte in a clinical sample loaded onto a self-contained test cartridge which is then inserted in the analyzer to automatically complete further steps to display the test result.
AFIAS-1 uses a single channel, it is optimized for small and mid-sized hospitals (or clinics) testing up to 10 samples per hour. For some tests, such as TSH, CRP, PCT, and HbA1c, a quantitative test can be performed using a small sample 30uL of whole blood from a finger or heel using an applicable C-tip (capillary tip).
For information to enhance your AFIAS-1 experience or if you'd like more information on our all in one cartridge release schedule contact us here.

The AFIAS-1 features
-
Fully Automatic
-
LIS Connectivity
-
1 Testing Channel
-
Capillary Blood, Serum or Plasma
-
5" LCD Touch Screen
-
Keyboard adaptable
Covid-19 Ab Test
Ready

AFIAS COVID-19 Ab Test Cartridge
AFIAS COVID-19 Ab test cartridge is an unitized, self-contained, ready-to-use test device to be used in conjunction with AFIAS-1 or AFIAS-6 analyzer by simply loading the clinical sample onto the test cartridge thereby offering great convenience to the user. AFIAS-1 and AFIAS-6 analyzers qualitatively detects IgG/IgM antibodies to SARS-CoV-2 in serum, plasma, venous whole blood or fingerstick capillary whole blood samples to automatically display the result after 10 minutes. The AFIAS COVID-19 Ab test cartridge is marked with a barcode, which signifies the identity of the test cartridge after sample-loaded test cartridge is inserted in and scanned by the analyzer
Detection Buffer Well

Sample Well
Detection Zone
Loading Well

AFIAS-1 Technical Specifications for AFIAS COVID-19 Ab test
Throughput
Number of channels
Sample
Cartridge
Measuring principle
Monitor/Keyboard
Calibration
Connectivity
Power Input
Dimension / Weight
Instrument type
Temp. Range
10 min per test
Single Channel
Serum/plasma/venous whole blood (150µL to be added in the sample well of the test cartridge) Fingerstick capillary whole blood to be collected into the AFIAS C-tip (30 µL) directly from the patient
Ready to use “all in one cartridge”
Lateral flow sandwich detection immunofluorescence assay
5” LCD touch screen, built-in thermal printer, bluetooth keyboard (optional)
Master calibration formula provided through lot-specific test ID Chip.
User-level calibration not required for AFIAS COVID-19 Ab test
Factory calibration, 2-point calibration / ID Chip (Master Calibration Curve)
LIS/HIS compatible, RS 232, USB port
100 ~ 240 V AC (50/60 Hz) / 1.5 A
320 mm (L) x 204 mm (W) x 180 mm (H) / 3.9kg
Compact Automatic Immunoassay Analyzer
15 ~ 35 °C

AFIAS-1 Resources


AFIAS-1 - Video Introduction
AFIAS-1 Test Introduction

AFIAS-1 - COVID-19
AFIAS-1 Covid-19 Testing

AFIAS - C-Tip Technology
AFIAS-1 C Tip Technology
Frequently Asked Questions
Having symptoms of weakness, dizziness, pale skin and cold hands and feet, Parents or other immediate family members have had a history of any blood disorder, If current diet is very low in iron and mineral content, Suffering from a long-term infection, They have suffered an excessive blood loss due to injury or surgical procedure, They are pregnant.
hema-screen SPECIFIC, a Fecal Immunochemical Test (FIT), is a rapid, convenient qualitative immunoassay for the determination of human hemoglobin in feces, a vital tool in the diagnosis and therapy of gastrointestinal disorders. Studies show that the following risk factors increase a person's chances of developing colorectal cancer:
• Age: colorectal cancer can occur at younger ages
• Diet (high in fat and calories and low in fiber or high in red or processed meat)
• Obesity; Physical inactivity; Cigarette smoking; Heavy alcohol consumption
• History or familial polyposis (parents, siblings, children
• Persons having ulcerative colitis or crohn’s disease
In comparison with guaiac-based testing the hema-screen SPECIFIC test has a higher specificity due to its unique combination of monoclonal and polyclonal antibodies that are specific to human-globin. A traditional guaiac test reacts with the peroxidase activity of heme protein in blood and is non-specific for human hemoglobin.
hema-screen™ SPECIFIC features an innovative sampling method that utilizes one card for collection of two (2) specimens of feces and ONLY one immunochemical specimen preparation tube/test cassette system for analysis. Advantages of utilizing the DEVEL-A-TAB sampler are as follows: thirty (30) days stability; and if the card is not returned the buffer tube and cassette are still useable. In addition, the replacement of the DEVEL-A-TAB sampler and mailing costs are reduced in comparison to the replacement of the buffer tube.
Since hema-screen™ SPECIFIC detects only blood from the lower GI tract where polyps and colorectal cancer develop, the test was found to be more accurate than a leading guaiac-based FOBT. In clinical studies, hema-screen™ SPECIFIC demonstrated a sensitivity of 98% and a specificity of 99%. When compared with a guaiac-based FOBT, hema-screen™ SPECIFIC demonstrated 33% greater sensitivity for occult blood.
There is no fecal handling involved when performing sample collections. Rather, samples are taken by defecating onto a tissue and using an applicator stick to stab the stool in 4-6 different sites. Once the sample is collected on the applicator lay the DEVEL-A-TAB sampler on a flat surface and apply the sample to window #1 by pulling the applicator stick across the entire window, making sure that the cavity is evenly filled and leveled. Close flap. Release tissue and FLUSH tissue and discard applicator stick.
Check that there is not excess specimen in the tube. Use stick attached to tube cap to loosen feces from sample strip if dispersion of specimen seems inadequate. Shake the tube vigorously (or vortex or rotator mix) to ensure the feces is well mixed with the buffer. Some small amount of fecal matter may not go into solution. There should not be any significant amount of undissolved fecal matter in the preparation tube. If the buffer flow along the test cassette appears to have stopped. First, tap cassette lightly on a hard surface, if flow does not continue, dispense one or more further drops into the test cassette well. If the test continues to not develop the patient should be supplied another collection kit and instructed to perform sample collection in accordance with the instructions for use. If there is no excess specimen and the test still does not develop within 5 minutes after the application of 2 additional drops of buffer, please contact Technical Services, Immunostics, Inc. in the US: 1-800-722-7505.
hema-screen SPECIFIC detects human blood in stool. There are many gastrointestinal conditions that may cause blood in stool, aside from colorectal cancer. If a patient receives a positive test result, more testing and evaluation is necessary and the American Cancer Society recommends follow-up with a colonoscopy.
Higher accuracy is achieved when testing is performed on two (2) consecutive fecal samples due to intermittent bleeding. The hema-screen SPECIFIC kit (Cat. №: HSSP-25) meets the American Cancer Society and the U.S. Task Force for Colorectal Cancer (CRC) Foundation recommendation of multiple-day testing.



